Irving Institute Announces New Pilot Awards to Fund COVID-19 Research
The Irving Institute for Clinical and Translational Research, home to Columbia University’s Clinical and Translational Science Award (CTSA)(link is external and opens in a new window) Program hub, announces the winners of two rapid response pilot programs to fund COVID-19 research.
The Irving Institute Translational Therapeutics (TRx) Accelerator, the Herbert Irving Comprehensive Cancer Center (HICCC) Accelerating Cancer Therapeutics (ACT) and Biomedical Engineering’s BiomedX(link is external and opens in a new window) launched a special pilot program to support projects focused on translating a therapeutic for treatment of COVID-19 toward commercialization. The 2020 TRx COVID-19 pilot awardees are:
Development of Cidofiovir Prodrugs as Potential Orally Available Medication for COVID-19
- Jingyue Ju, PhD, Chemical Engineering
Rapid Development of SARS-CoV-2 3CL Protease Inhibitors for treatment of COVID-19
- Brent Stockwell, PhD, Biological Sciences
Adoptive Transfer of Coronavirus-specific T Cells for Prophylaxis and Immunotherapy of COVID-19
- Pawel Muranski, MD, Medicine
In partnership with the HICCC, the Irving Institute is also supporting the following SARS-CoV-2 (COVID-19) Research pilot grantees:
Identification of adverse SARS-CoV-2 infection outcome determinants
- Sagi Shapira, PhD, Systems Biology (in Microbiology and Immunology)
Novel technologies to identify SARS-CoV-2 therapeutics
- Hee Yang, PhD, Pathology & Cell Biology
Smartphone-enabled home serology tests for large-scale, accurate, and trackable, COVID-19 testing and surveillance
- Samuel K. Sia, PhD, Biomedical Engineering
We congratulate the awardees and are proud to support this timely research. View the Irving Institute's COVID-19 Research Initiative to learn more about how we are addressing the pandemic.